Payment overview · 2025
General Payments
$420.83
23 reported records · 11 companies
Healthcare provider profile · identity verified
Joe Lee Perryman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ARLINGTON, TX · NPI 1649224312
Verified facts
What the public records show
CMS Open Payments records show Joe Lee Perryman, MD received $420.83 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.59 | 22.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.31 | 11.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.40 | 11.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.40 | 8.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.62 | 8.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.06 | 7.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.51 | 7.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.44 | 7.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.38 | 6.0% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.48 | 5.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $420.83 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.59 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.59 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.31 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.51 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.44 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 267 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 215 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
267 | 54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
267 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
215 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1252 | 388 |
| Levothyroxine Sodium | Levothyroxine Sodium | 903 | 243 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 882 | 282 |
| Amlodipine Besylate | Amlodipine Besylate | 820 | 251 |
| Lisinopril | Lisinopril | 779 | 236 |
| Metformin Hcl | Metformin Hcl | 539 | 167 |
| Losartan Potassium | Losartan Potassium | 439 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 132 |
| Furosemide | Furosemide | 345 | 87 |
| Gabapentin | Gabapentin | 338 | 79 |
| Omeprazole | Omeprazole | 316 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 314 | 42 |
| Carvedilol | Carvedilol | 305 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 95 |
| Jardiance | Empagliflozin | 267 | 54 |
| Simvastatin | Simvastatin | 252 | 79 |
| Montelukast Sodium | Montelukast Sodium | 246 | 75 |
| Potassium Chloride | Potassium Chloride | 244 | 69 |
| Alprazolam | Alprazolam | 233 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 78 |
| Ozempic | Semaglutide | 215 | 38 |
| Eliquis | Apixaban | 213 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 64 |
| Sertraline Hcl | Sertraline Hcl | 207 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 204 | 40 |
| Allopurinol | Allopurinol | 203 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 169 | 51 |
| Meloxicam | Meloxicam | 169 | 59 |
| Trazodone Hcl | Trazodone Hcl | 166 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 44 |
| Ezetimibe | Ezetimibe | 159 | 58 |
| Tramadol Hcl | Tramadol Hcl | 154 | 27 |
| Glimepiride | Glimepiride | 151 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 53 |
| Alendronate Sodium | Alendronate Sodium | 136 | 43 |
| Famotidine | Famotidine | 129 | 35 |
| Telmisartan | Telmisartan | 119 | 38 |
| Mirtazapine | Mirtazapine | 109 | 22 |
| Metformin Hcl Er | Metformin Hcl | 101 | 38 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 95 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 31 |
| Synthroid | Levothyroxine Sodium | 90 | 28 |
| Cefdinir | Cefdinir | 88 | 77 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 23 |
| Nifedipine Er | Nifedipine | 86 | 18 |
| Methocarbamol | Methocarbamol | 85 | 22 |
| Donepezil Hcl | Donepezil Hcl | 84 | 16 |
| Levetiracetam | Levetiracetam | 82 | 13 |
| Pregabalin | Pregabalin | 80 | 14 |
| Atenolol | Atenolol | 79 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 24 |
| Glipizide Er | Glipizide | 73 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 22 |
| Januvia | Sitagliptin Phosphate | 72 | suppressed |
| Celecoxib | Celecoxib | 71 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 26 |
| Memantine Hcl | Memantine Hcl | 63 | 16 |
| Rybelsus | Semaglutide | 63 | 16 |
| Buspirone Hcl | Buspirone Hcl | 61 | 22 |
| Lorazepam | Lorazepam | 60 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 16 |
| Eszopiclone | Eszopiclone | 56 | suppressed |
| Temazepam | Temazepam | 56 | 11 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 18 |
| Trulicity | Dulaglutide | 54 | 13 |
| Valsartan | Valsartan | 54 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 40 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 21 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Finasteride | Finasteride | 51 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Glipizide | Glipizide | 49 | 15 |
| Clonazepam | Clonazepam | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Spironolactone | Spironolactone | 46 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 44 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | 11 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 17 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Prednisone | Prednisone | 39 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 14 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | 13 |
| Folic Acid | Folic Acid | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 12 |
| Bupropion Xl | Bupropion Hcl | 35 | 13 |
| Clonidine Hcl | Clonidine Hcl | 35 | 12 |
| Irbesartan | Irbesartan | 35 | 12 |
| Calcitriol | Calcitriol | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | 13 |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 12 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | 13 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Linzess | Linaclotide | 29 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Nateglinide | Nateglinide | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Acyclovir | Acyclovir | 22 | 11 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Clonidine | Clonidine | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Viibryd | Vilazodone Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $420.83 · 23 records | Novo Nordisk Inc | AIRSUPRA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, Ozempic, Rybelsus, VYKAT XR, Veozah, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error